Mylan
1000 Mylan Boulevard
Canonsburg
Pennsylvania
15317
United States
Tel: 724-514-1800
Website: http://www.mylan.com/
About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, Mylan innovates to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership
YEAR FOUNDED:
1961
LEADERSHIP:
Founders: Milan Puskar, and Don Panoz
CEO: Heather Bresch
CFO: Neil Dimick
PRODUCTS:
All Products
866 articles with Mylan
-
Mylan Again Defeats Allergan's Efforts to Deny Patients Access to More Affordable Medicine
7/20/2018
Global Pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the U.S. Patent Trial and Appeal Board (PTAB), which found that tribal sovereign immunity cannot apply to prevent inter partes review (IPR) proceedings.
-
AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan
7/17/2018
AbbVie announced patent license agreements with Mylan over its proposed biosimilar adalimumab product.
-
AbbVie continues to do what it can to protect its Humira-driven revenue stream. This morning the company inked an agreement to grant Mylan the rights to begin marketing its biosimilar to Humira in the United States in 2023.
-
The U.S. Food and Drug Administration (FDA) was busy during the first half of this year with more than 20 novel drug approvals. Of those approvals, one-third came in June.
-
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon® Patch
7/9/2018
Mylan N.V. today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis' Exelon® Patch.
-
The U.S. Food and Drug Administration withdrew its draft guidance on statistical methods to evaluate the analytical similarity between branded drugs and biosimilars.
-
Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.
-
Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar
6/28/2018
Through the partnership agreement, Mylan will commercialize Lupin's proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.
-
Not only are women generally underrepresented in the biopharma industry, but compared to many of the top male executives, underpaid. Here’s a closer look at the top five female executives by pay in the biopharma industry.
-
Mylan Launches Generic Angiomax® Injection
6/18/2018
Bivalirudin for Injection is an anticoagulant intended for use with aspirin
-
Dr. Reddy’s, Mylan Secure Approval for Suboxone Generic, Shares of Indivior Fall on the News
6/15/2018
Shares of Dr. Reddy’s Laboratories Ltd. are surging this morning after the FDA approved its generic version of Suboxone (buprenorphine and naloxone) sublingual film for opioid addiction. -
In a brief statement, Mylan reported that the U.S. Food and Drug Administration (FDA) had informed the company that its Generic Advair Diskus had “minor deficiencies” that would be in a Complete Response Letter.
-
Americares Honors Mylan with Power of Partnership Award
6/11/2018
Award Presented at HDA Business and Leadership Conference
-
The U.S. Food and Drug Administration (FDA) approved Mylan’s Fulphila (pegfilgrastim-jmbd), a biosimilar to Amgen’s Neulasta (pegfilgrastim). The biosimilar was co-developed with Biocon.
-
U.S. FDA Approves Mylan and Biocon's Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®
6/4/2018
Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's Fulphila™ (pegfilgrastim-jmbd).
-
Mylan to Present at Goldman Sachs 39th Annual Global Healthcare Conference
6/1/2018
CEO Heather Bresch will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA, on Wednesday, June 13, 2018, at 1:20 p.m. PT / 4:20 p.m. ET.
-
Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin® approved by FDA
6/1/2018
Mylan N.V. and Biocon Ltd. announced that 48-week results from the HERITAGE study will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Evolus for its Biologics License Application (BLA) for DWP-450 (prabotulinumtoxinA), a drug to treat frown lines similar to Allergan’s Botox.
-
Shares of Perrigo have yet to rebound following the company’s weekend announcement that it expects the U.S. Food and Drug Administration to issue a Complete Response Letter for its generic version of Teva’s ProAir asthma inhaler.
-
Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance
5/9/2018
Total revenues of $2.68 billion, down 1% compared to the prior year period.